Table 2:
Change in endpoint before and during tolvaptan or before and after theoretical start of treatment.
| Tolvaptan | |||||
|---|---|---|---|---|---|
| Endpoint | Before treatment | Acute slope | Chronic slope | P-value a | P-value b |
| N = 98, n = 308 | N = 69, n = 70 | N = 105, n = 656 | |||
| eGFR slope, mL/min/1.73 m2/year | –4.28 (–4.86 to –3.72) | –9.56c (–16.86 to –2.25) | –3.68 (–4.24 to –3.11) | .02 | .02 |
| N = 63, n = 122 | N = 79, n = 204 | ||||
| TKV growth, %/year | 4.88 (2.84 to 6.99) | NA | 5.64 (3.46 to 7.81) | NA | .4 |
| No tolvaptan | |||||
| Before theoretical treatment | Acute slope | Chronic slope | P-value a | P-value b | |
| N = 510, n = 1152 | N = 42, n = 42 | N = 510, N = 1525 | |||
| eGFR slope, mL/min/1.73 m2/year | –1.97 (–2.35 to –1.58) | 2.67c (–2.38 to 7.72) | –2.16 (–2.58 to –1.75) | .3 | .3 |
| N = 360, n = 391 | N = 360, n = 547 | ||||
| TKV growth, %/year | 4.62 (3.15 to 6.12) | NA | 4.69 (3.20 to 6.20) | NA | .9 |
Fixed effects were first measured eGFR or TKV, and an interaction term of time in years with tolvaptan use (before treatment/acute slope/chronic slope) or theoretical start of treatment (before theoretical treatment/acute slope/chronic slope). Random effects were time and patients. Table shows estimates and 95% CI. For the no tolvaptan group values are calculated until and from the theoretical start of treatment. The start of chronic slope was chosen to be at 6 weeks after start of (theoretical) treatment.
Comparison between values before (theoretical) treatment and (theoretical) acute phase.
Comparison between before (theoretical) treatment and during (theoretical) treatment.
cAcute slope is described in mL/min/1.73 m2/6 weeks.
N, number of patients; n, number of measurements.